Corporate Profile

Vardhman Chemtech Limited was incorporated in year 1996, but started its operations in year 1999 as a single reactor plant for recovery from waste. Currently the Company is one of the largest and most integrated manufacturers of Bulk Drugs, Intermediates and Fine Chemicals in India in the oral and sterile Isoxazoles segment of Penicillin (Cloxacillin Sodium, Dicloxacillin Sodium, Flucloxacillin Sodium, Oxacillin Sodium) with an installed capacity of 1400 TPA and 400 TPA respectively. The company commissioned its sterile API’s (injectable) facility in FY 2010-11 thus making it India’s second largest sterile penicillin facility. With the commissioning of sterile plant and full utilization of projects implemented last year, the Company has achieved a turnover of Rs. 385 Crores in FY 2011-12.

Our facilities deploy state-of-the-art technologies and automated facilities that ensure the highest levels of process integrity and product quality. Our Sterile plant has been laid down as per guidelines of US-FDA/ EU-GMP guidelines, cGMP standards, fabrication and support systems. The infrastructure meets the world-class standards.

Vardhman Chemtech Ltd. has built up a reputation for quality and excellence on the foundations of constantly expanding product portfolio, timely deliveries, and state-of-the-art manufacturing facilities, conforming to the most stringent international standards. We have earned accolades from our customers not only in domestic market but also in the international market due to our unwavering commitment towards quality and customer satisfaction.

Marketing Network:
The company forayed into exports in year 2007 and within a short span of four and a half years, our products are being exported in more than 40 countries. The company has achieved this feet in such a short span due to its continuously upgrading R&D capabilities, patented technologies and manufacturing expertise.

At the moment, the Company is focusing on the emerging markets like South East Asia, Africa, Latin America and Russia. The Company is looking forward to increase exports, and plans to take its sterile products portfolio to the Regulatory markets such as Europe and USA by FY 2013-14.

Expanding horizon:
Vardhman Group has acquired a facility spread over 60 acres in Cuddalore near Pondicherry and the Company is likely to commission this multi-production facility for manufacturing API’s (Potassium Clavulanate – Oral & Sterile) in the Second quarter of FY 2012-13.

Vardhman is a young, growing and dynamic pharmaceutical group specialized in manufacturing of quality Bulk Drugs, Intermediates, and fine Chemicals and is poised to achieve excellence on strength of its strong R&D base, motivated team, concern for safety, health, environment and commitment to do business with ethics.